ArticleCell adhesion & migration2025
Loss of CDS1 impairs the tumorigenic characteristics of nasopharyngeal carcinoma by modulating lipid metabolism.
Article in Cell adhesion & migration, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The accumulation of lipid droplets (LDs) enhancing nasopharyngeal carcinoma (NPC) cell migration. We reveals that CDP-diacylglycerol synthase 1 (CDS1), an inhibitor of LDs formation, is significantly downregulated in NPC. Restoring CDS1 expression suppresses NPC cell growth, colony formation, tumorigenesis, migration, and invasion. The anti-cancer effect of CDS1 is attributed to its role in decreasing the intracellular LDs. Moreover, CDS1 promotes activation of the NF-κB signaling pathway, resulting in elevated levels of inflammatory cytokines within NPC cells. This is likely to enhance the immunogenicity of these cells, thereby reducing tumor volume in the in vivo model. These findings establish CDS1 as a novel suppressor of NPC by modulating LDs levels, suggesting potential therapeutic avenues aimed at limiting LDs accumulation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.